Brown, Lisle/Cummings’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.31M Sell
27,953
-1,043
-4% -$267K 1.61% 12
2026
Q2
$7.3M Buy
28,996
+139
+0.5% +$29.9K 1.64% 12
2026
Q1
$6.28M Buy
28,857
+278
+1% +$61.7K 1.57% 11
2025
Q4
$6.53M Buy
28,579
+534
+2% +$122K 1.61% 11
2025
Q3
$6.49M Hold
28,045
– – 1.67% 11
2025
Q2
$5.21M Sell
28,045
-174
-0.6% -$32.3K 1.39% 16
2025
Q1
$5.91M Buy
28,219
+181
+0.6% +$35.2K 1.71% 10
2024
Q4
$4.98M Sell
28,038
-53
-0.2% -$9.7K 1.49% 12
2024
Q3
$5.55M Buy
28,091
+1,450
+5% +$271K 1.69% 11
2024
Q2
$4.57M Buy
26,641
+1,124
+4% +$186K 1.49% 13
2024
Q1
$4.65M Hold
25,517
– – 1.58% 12
2023
Q4
$3.95M Buy
25,517
+4,025
+19% +$587K 1.47% 12
2023
Q3
$3.2M Buy
21,492
+425
+2% +$62.4K 1.45% 17
2023
Q2
$2.84M Buy
21,067
+1,125
+6% +$165K 1.27% 20
2023
Q1
$3.18M Sell
19,942
-26
-0.1% -$3.98K 1.61% 12
2022
Q4
$3.23M Sell
19,968
-953
-5% -$146K 1.73% 10
2022
Q3
$2.81M Hold
20,921
– – 1.64% 13
2022
Q2
$3.2M Sell
20,921
-7
-0% -$1.07K 1.77% 13
2022
Q1
$3.39M Buy
20,928
+65
+0.3% +$9.44K 1.63% 13
2021
Q4
$2.82M Buy
+20,863
New +$2.46M 1.41% 15

Other funds holding ABBV

Brown, Lisle/Cummings's ABBV Position: Q3 2026 in Review

Brown, Lisle/Cummings reduced its AbbVie (ABBV) stake by 3.6% in Q3 2026, selling an estimated $267K and leaving 27,953 shares worth $7.31M. The position accounts for 1.61% of the portfolio, ranked #12.

Brown, Lisle/Cummings first reported a position in ABBV in Q4 2021 and has held it in 20 quarters since. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Brown, Lisle/Cummings held 27,953 shares of AbbVie worth $7.31M as of Q3 2026.
  • Brown, Lisle/Cummings sold 1,043 AbbVie shares in Q3 2026, an estimated $267K.
  • AbbVie made up 1.61% of Brown, Lisle/Cummings's portfolio in Q3 2026, its #12 holding.
  • Brown, Lisle/Cummings first reported a position in AbbVie in Q4 2021 and has held it in 20 quarters since.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q3 2026, filed 16 Oct 2026.